


#2



JCO7 Reg PCT/PTO 27 APR 2005

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

YAMADA, Yoshiji, et al.

Group Art Unit: Not Yet Assigned

Serial No.: 10/528,659

Examiner: Not Yet Assigned

Filed: March 22, 2005

Confirmation No. Not Yet Assigned

For: METHOD OF PREDICTING GENETIC RISK FOR HYPERTENSION

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 27, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

Documents AN through BH are discussed in the subject specification. Documents BH through BL are cited in the International Search Report, and are enclosed herewith, except for Document BL. The International Search Report was previously filed on March 22, 2005.

No fee is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

Serial No.: 10/528,659
IDS filed April 27, 2005

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS, HANSON & BROOKS, LLP



Donald W. Hanson
Attorney for Applicants
Reg. No. 27,133


Atty. Docket No. 050174
Suite 1000, 1725 K Street, N.W.
Washington, D.C. 20006
(202) 659-2930
DWH/nk



23850

PATENT TRADEMARK OFFICE

Enclosures: PTO1449 (3 pages), 24 References



INFORMATION DISCLOSURE CITATION PTO-1449	Atty. Docket No. 050172	Serial No. 10/528,659
	Applicant(s): Yamada et al	
	Filing Date: 3/22/05	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS


Examiner Initial	Document No.	Name	Date	Class	Sub class	Filing Date (If appropriate)
_____	AA					
_____	AB					
_____	AC					
_____	AD					
_____	AE					

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____	AF		
_____	AG		
_____	AH		
_____	AI		
_____	AJ		
_____	AK		
_____	AL		
_____	AM		

OTHER DOCUMENTS

_____	AN	Lifton R.P. et al. Molecular mechanisms of human hypertension. Cell. 2001; 104:545-556.		
_____	AO	Xu X., et al. An extreme-sib-pair genome scan for genes regulating blood pressure. Am J Hum Genet. 1999;64:1694-1701.		
_____	AP	Krushkal J. et al. Genome-wide linkage analysis of systolic blood pressure using highly discordant siblings. Circulation. 1999;99:1407-1410.		
_____	AQ	Rice T. et al. Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study. Circulation. 2000;102:1956-1963.		
<table border="1"> <tr> <td>Examiner</td> <td>Date Considered</td> </tr> </table>			Examiner	Date Considered
Examiner	Date Considered			




INFORMATION DISCLOSURE CITATION PTO-1449	Atty. Docket No. 050174	Serial No. 10/528,659
	Applicant(s): Yamada et al	
	Filing Date: 3/22/05	Group Art Unit: Not Yet Assigned

OTHER DOCUMENTS CONTINUED

_____	AR	Jeunemaitre X. et al. Molecular basis of human hypertension: Role of Angiotensinogen. Cell. 1992;71:169-180.
_____	AS	Cusi D. et al. Polymorphisms of α -adducin and salt sensitivity in patients with essential hypertension. Lancet. 1997;349:1353-1357.
_____	AT	Siffert W. et al. Association of a human G-protein $\beta 3$ subunit variant with hypertension. Nat Genet. 1998;18:45-48.
_____	AU	Bray M.S. et al. Positional genomic analysis identifies the β_2 -Adrenergic receptor gene as a susceptibility locus for hypertension. Circulation. 2000; 101:2877-2882.
_____	AV	Pausova Z. et al. Role of tumor necrosis factor- α gene locus in obesity and obesity-associated hypertension in French Canadians. Hypertension. 2000;36: 14-19.
_____	AW	Frossard P.M. et al, A study of five human cytokine genes in human essential hypertension. Mol. Immunol. 2002; 38:969-976.
_____	AX	Zinman B. et al. Circulating tumor necrosis factor- α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin. Endocrinol. Metab. 1999;84:272-278.
_____	AY	Kahaleh M.B. et al. Effect of cytokines on the production of endothelin by endothelial cells. Clin. Exp. Rheumatol. 1997;15:163-167.
_____	AZ	Winkler G. et al. Elevated serum TNF- α level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabetic Med. 1999;16:207-211.
_____	BA	Tas S. et al. Blood pressure, coronary artery disease, and glycaemic control in type 2 diabetes mellitus: relation to apolipoprotein-CIII gene polymorphism. Lancet. 1994;343:1194-1195.
_____	BB	Bush E. et al. CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension. 2000;36:360-363.
_____	BC	Abe H. et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J. Clin. Invest. 1998;101:1784-1788.
_____	BD	Andrioli G. et al, Study of platelet adhesion in patients with uncomplicated hypertension. J. Hypertension. 1996;14:1215-1221.

Examiner	Date Considered
----------	-----------------



INFORMATION DISCLOSURE CITATION PTO-1449	Atty. Docket No. 050174	Serial No. 10/528,659
	Applicant(s): Yamada et al	
	Filing Date: 3/22/05	Group Art Unit: Not Yet Assigned

OTHER DOCUMENTS CONTINUED

_____	BE	Dockrell M. E. et al. Platelet aggregation in young men contrasting predisposition to high blood pressure. Am. J. Hypertension. 1999;12:115-119.
_____	BF	Bereczki, Cs. et al. The roles of platelet function, thromboxane, blood lipids, and nitric oxide in hypertension of children and adolescents. Prostaglandins Leukot. Essent. Fatty Acids. 2000;62:293-297.
_____	BG	Murata M. et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation. 1997;96:3281-6.
_____	BH	Kroll, H. et al. The impact of the glycoprotein Ia collagen receptor subunit A ₁₆₄₈ G gene polymorphism on coronary artery disease and acute myocardial infarction. Thromb Haemost. 2000;83:392-396.
_____	BI	Nicolas von Beckerath et al. "G Protein β 3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement" Atherosclerosis, 2000, 149, 151-155
_____	BJ	Juliano C. Padovani et al. "Gene Polymorphisms in the TNF Locus and the Risk of Myocardial Infarction" Thrombosis Research, 2000, 100, 263-269
_____	BK	Douglas H. et al. "Platelet member glycoprotein Iba gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis" Heart, 2002, 87, 70-74
_____	BL	Ashavaid, T. et al. " Gene polymorphism and coronary Risk Factor in Indian Population" Clinical Chemistry and Laboratory Medicine, 2002, 40(10), 975-985
Examiner _____ Date Considered _____		